Trials / Completed
CompletedNCT02114658
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to evaluate safety, efficacy and pharmacokinetics of sorafenib for the treatment of Japanese patients with anaplastic thyroid carcinoma (ATC) or locally advanced or metastatic medullary thyroid carcinoma (MTC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar,BAY43-9006) | Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle |
Timeline
- Start date
- 2014-04-15
- Primary completion
- 2015-02-23
- Completion
- 2016-08-02
- First posted
- 2014-04-15
- Last updated
- 2017-08-03
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02114658. Inclusion in this directory is not an endorsement.